Shufro Rose & Co. LLC cut its position in SPDR S&P Biotech (NYSEARCA:XBI) by 2.0% during the second quarter, Holdings Channel reports. The institutional investor owned 9,700 shares of the exchange traded fund’s stock after selling 200 shares during the period. Shufro Rose & Co. LLC’s holdings in SPDR S&P Biotech were worth $749,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in XBI. FineMark National Bank & Trust increased its position in SPDR S&P Biotech by 7.4% in the second quarter. FineMark National Bank & Trust now owns 5,210 shares of the exchange traded fund’s stock worth $402,000 after buying an additional 360 shares in the last quarter. Janney Montgomery Scott LLC increased its position in SPDR S&P Biotech by 10.9% in the second quarter. Janney Montgomery Scott LLC now owns 98,057 shares of the exchange traded fund’s stock worth $7,568,000 after buying an additional 9,655 shares in the last quarter. Boston Advisors LLC purchased a new position in SPDR S&P Biotech during the second quarter worth approximately $213,000. Benjamin F. Edwards & Company Inc. increased its position in SPDR S&P Biotech by 4.1% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 8,692 shares of the exchange traded fund’s stock worth $671,000 after buying an additional 346 shares in the last quarter. Finally, Meridian Wealth Management LLC purchased a new position in SPDR S&P Biotech during the second quarter worth approximately $432,000.

SPDR S&P Biotech (NYSEARCA:XBI) opened at 76.47 on Wednesday. The company has a 50-day moving average price of $78.27 and a 200-day moving average price of $71.88. SPDR S&P Biotech has a 12-month low of $53.15 and a 12-month high of $82.38.

COPYRIGHT VIOLATION WARNING: This article was posted by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.watchlistnews.com/shufro-rose-co-llc-reduces-stake-in-spdr-sp-biotech-xbi/1494106.html.

SPDR S&P Biotech Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech and related companies with Analyst Ratings Network's FREE daily email newsletter.